Cargando…
Future possibilities in the prevention of breast cancer: Luteinizing hormone-releasing hormone agonists
The cyclic production of estrogen and progesterone by the premenopausal ovary accounts for the steep rise in breast cancer risk in premenopausal women. These hormones are breast cell mitogens. By reducing exposure to these ovarian hormones, agonists of luteinizing hormone-releasing hormone (LHRH) gi...
Autores principales: | Spicer, Darcy V, Pike, Malcolm C |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138786/ https://www.ncbi.nlm.nih.gov/pubmed/11250719 http://dx.doi.org/10.1186/bcr67 |
Ejemplares similares
-
Long-Acting Luteinizing Hormone-Releasing Hormone Agonist for Ovarian Hyperstimulation Induced by Tamoxifen for Breast Cancer
por: Kojima, Nobue, et al.
Publicado: (2018) -
Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women
por: Lu, Yen-Shen, et al.
Publicado: (2021) -
Luteinizing hormone-releasing hormone agonists versus orchiectomy in the treatment of prostate cancer: A systematic review
por: Zhang, Xianlu, et al.
Publicado: (2023) -
Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist.
por: Nicholson, R. I., et al.
Publicado: (1979) -
Progression of Intracranial Meningioma during Luteinizing Hormone-Releasing Hormone Agonist Treatment for Prostate Cancer: Case Report
por: ANDA, Takeo, et al.
Publicado: (2014)